IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
Paul M. RidkerCenter for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: [email protected]Matt DevalarajaFlorian M.M. BaeresNovo Nordisk, Bagsvaerd, DenmarkMads D.M. EngelmannNovo Nordisk, Bagsvaerd, DenmarkG. Kees HovinghNovo Nordisk, Bagsvaerd, DenmarkMilana IvkovicNovo Nordisk, Bagsvaerd, DenmarkLarry LoDouglas KlingPablo E. PérgolaRenal Associates, San Antonio, TX, USADominic S. RajDivision of Kidney Diseases and Hypertension, George Washington University, Washington, DC, USAPeter Libbythe Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USAMichael Davidson
2021en
ABI
Annotatsiya
Annotatsiya mavjud emas.
Identifikatorlar
Iqtiboslar va manbalar
2 ta iqtibos0 ta foydalanilgan manba